Novel human interleukin-4 receptor-binding nanobody and nasal spray formulation comprising same
Nanobodies with enhanced IL-4R binding affinity, administered as a nasal spray, overcome the limitations of traditional antibodies by directly targeting IL-4R in the nasal epithelium, providing effective inflammation treatment with reduced side effects.
Patent Information
- Application Number
- PCT/KR2024/006903
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-28
AI Technical Summary
Conventional anti-IL-4R antibodies, due to their large molecular weight, cannot penetrate epithelial cells and thus require systemic administration, leading to side effects and limited efficacy in treating inflammatory diseases like chronic sinusitis with nasal polyps.
Development of nanobodies with optimized amino acid sequences and mutations, such as SEQ ID NOs. 1 and 5, for enhanced receptor binding affinity, administered as a nasal spray to directly target IL-4R in the nasal epithelium, maximizing therapeutic effect while minimizing side effects.
The nanobody formulation effectively prevents or treats inflammation in the nasal epithelium without systemic side effects, demonstrating superior binding affinity and cell permeability compared to dupilumab, thereby addressing the limitations of traditional antibody therapies.
Smart Images

Figure KR2024006903_28112024_PF_FP_ABST
Abstract
Description
Novel human interleukin-4 receptor-binding nanobody and nasal spray formulation comprising the same
[0001] The present invention relates to a nanobody that specifically binds to an IL-4 receptor, a nasal spray containing the same as an active ingredient, and a method for preventing or treating various IL-4-mediated inflammatory diseases using the same as a pharmacological ingredient.
[0002]
[0003] The hollow spaces within the facial bones surrounding the nose are called paranasal sinuses. These spaces are connected to the inside of the nose through small openings called ostia, which allow for ventilation and drainage of paranasal secretions. Sinusitis, or sinusitis, occurs when these ostia become blocked, hindering proper ventilation and drainage of the sinuses. This secondary inflammation occurs, leading to the accumulation of purulent secretions and the subsequent worsening of the inflammation. When sinusitis persists for more than three months, it is defined as chronic rhinosinusitis (CRS).
[0004] Among these chronic sinusitis cases, cases accompanied by nasal polyps account for up to 33% of all sinusitis cases, and are known to be accompanied by various respiratory diseases and have a poor prognosis even after endoscopic sinus surgery.
[0005] Dupilumab, a monoclonal antibody against interleukin-4R-α, has been shown to be effective in treating chronic sinusitis. However, due to the size of the antibody, direct administration to the affected area is impossible, and it is currently only available as an injection, which has the fatal drawback of causing various side effects such as injection site reaction or serum sickness-like reactions. "Nanobody" corresponds to the antigen recognition variable region of a heavy chain-only antibody discovered in camelids, and its small molecular weight and high production yield can provide a solution to various problems, including limitations in administration methods of existing general antibody treatments.
[0006] Meanwhile, in the case of artificial intelligence-based structure prediction (in silico affinity maturation) technology, it is very useful for maximizing the receptor binding ability of nanobodies by predicting the structure of antigen-binding fragments such as nanobodies, identifying the binding structure with the receptor, and then discovering mutations that can increase binding affinity to the receptor through a computer program-based binding affinity enhancement technique.
[0007] Accordingly, the present inventors have discovered a new type of IL-4R inhibitory antibody that exhibits a significantly higher IL-4 receptor inhibitory effect compared to the existing dupilumab, while also having high stability and a small molecular weight, which can be administered through various methods, especially by directly administering it to nasal epithelial cells in the form of a spray, thereby penetrating the epithelial cells and eliminating inflammation. In addition, the inventors have attempted to develop a mutant antibody with maximized binding affinity through a computer program-based binding affinity enhancement technique for the discovered antibody.
[0008]
[0009] Numerous papers and patents are referenced and cited throughout this specification. The disclosures of these cited papers and patents are incorporated herein by reference in their entirety to provide a clearer understanding of the state of the art and the scope of the present invention.
[0010]
[0011] The present inventors have made extensive research efforts to improve the problems of conventional anti-IL-4R antibodies, which have excellent therapeutic effects on various inflammatory diseases including sinusitis as inhibitors of the IL-4 receptor, but cannot pass through epithelial cells due to their large molecular weight, so they are administered only as injections, which entails many side effects. As a result, the inventors have developed a nanobody comprising an antigen-binding fragment having the amino acid sequence of SEQ ID NOS: 1 and 5, and further an amino acid substitution mutation that can further maximize their receptor binding affinity, and have discovered that when this is directly administered locally to the inflamed area of the paranasal sinus in the form of a nasal spray, inflammation can be effectively prevented or treated without side effects, thereby completing the present invention.
[0012] Accordingly, the purpose of the present invention is to provide an antibody or an antigen-binding fragment thereof for IL-4 receptor (IL-4R) and a nucleic acid molecule encoding the same.
[0013] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases that can also be applied in the form of a nasal spray.
[0014] Other objects and advantages of the present invention will become more apparent from the detailed description, claims and drawings below.
[0015]
[0016] According to one aspect of the present invention, the present invention provides an anti-IL-4R antibody or antigen-binding fragment thereof comprising an amino acid sequence of SEQ ID NO: 1 comprising a substitution of at least one amino acid residue selected from the group consisting of the 5th residue and the 11th residue.
[0017] The present inventors have made extensive research efforts to improve the problems of conventional anti-IL-4R antibodies, which have excellent therapeutic effects on various inflammatory diseases including sinusitis as inhibitors of the IL-4 receptor, but cannot pass through epithelial cells due to their large molecular weight, so they are administered only as injections, which entails many side effects. As a result, we developed a nanobody comprising an antigen-binding fragment having the amino acid sequences of SEQ ID NOs: 1 and 5, and further, an amino acid substitution mutation that can further maximize their receptor binding affinity. We discovered that when this is administered directly to the inflamed area of the paranasal sinus in the form of a nasal spray, it can effectively prevent or treat inflammation without side effects.
[0018] The term “antibody” as used herein means an antibody against IL-4-R, which is a peptide that specifically recognizes and binds to a specific epitope thereof, and includes not only a complete antibody form but also an antigen-binding fragment (antibody fragment) of the antibody molecule.
[0019] A complete antibody has two full-length light chains and two full-length heavy chains, each light chain linked to a heavy chain by a disulfide bond. The heavy chain constant regions are of the gamma (γ), mu (μ), alpha (α), delta (δ), and epsilon (ε) types, and are subclassed into gamma1 (γ1), gamma2 (γ2), gamma3 (γ3), gamma4 (γ4), alpha1 (α1), and alpha2 (α2). The light chain constant regions are of the kappa (κ) and lambda (λ) types.
[0020] The term “antigen-binding fragment of an antibody” as used herein means a fragment having significant antigen-antibody binding function within the entire antibody molecule, and includes Fab, F(ab'), F(ab')2, Fv, and nanobody (or sybody).
[0021] Among antibody fragments, Fab has a structure with variable regions of the light and heavy chains, a constant region of the light chain, and the first constant region (CH1) of the heavy chain, and has one antigen-binding site. Fab' differs from Fab in that it has a hinge region containing one or more cysteine residues at the C-terminus of the CH1 domain of the heavy chain. F(ab')2 antibodies are produced when the cysteine residues in the hinge region of Fab' form a disulfide bond. Fv is the minimum antibody fragment that has only the heavy chain variable region and the light chain variable region, and recombinant techniques for producing Fv fragments are disclosed in WO88 / 10649, WO88 / 106630, WO88 / 07085, WO88 / 07086, and WO88 / 09344. A two-chain Fv has a heavy chain variable region and a light chain variable region linked non-covalently, and a single-chain Fv has a heavy chain variable region and a single chain variable region covalently linked, usually via a peptide linker, or directly linked at the C-terminus, so that they can form a dimer-like structure like a two-chain Fv. These antibody fragments can be obtained using proteolytic enzymes (for example, restriction digestion of a whole antibody with papain yields a Fab fragment, and digestion with pepsin yields an F(ab')2 fragment), or can be produced through genetic recombination technology.
[0022] The term “heavy chain” as used herein refers to a full-length heavy chain and fragments thereof comprising a variable region domain VH comprising an amino acid sequence having sufficient variable region sequence to confer specificity for an antigen and three constant region domains CH1, CH2 and CH3.
[0023] The term “light chain” as used herein refers to both full-length light chains and fragments thereof comprising a variable region domain VL and a constant region domain CL, which comprise an amino acid sequence having sufficient variable region sequence to confer specificity for an antigen.
[0024] As used herein, the term “complementarity determining region (CDR)” refers to the amino acid sequence of the hypervariable region of the immunoglobulin heavy and light chains (Kabat et al. Sequences of Proteins of Immunological Interest, 4th Ed., US Department of Health and Human Services, National Institutes of Health (1987)). The heavy chain (HCDR1, HCDR2, and HCDR3) and the light chain (LCDR1, LCDR2, and LCDR3) each contain three CDRs, which provide key contact residues for antibody binding to an antigen or epitope. The scope of the antibody or antibody fragment of the present invention includes variants having conservative amino acid substitutions in the CDR regions. In addition, the antibody or antibody fragment of the present invention may include variants of the amino acid sequences set forth in the attached sequence listing within the range capable of specifically recognizing the IL-4 receptor. For example, additional changes can be made to the amino acid sequence of an antibody to further improve its binding affinity and / or other biological properties. Such modifications include, for example, deletions, insertions, and / or substitutions of amino acid sequence residues of the antibody. These amino acid mutations are made based on the relative similarity of the amino acid side-chain substituents, such as hydrophobicity, hydrophilicity, charge, size, etc. Analysis of the size, shape, and type of amino acid side-chain substituents reveals that arginine, lysine, and histidine are all positively charged residues; alanine, glycine, and serine are similar in size; and phenylalanine, tryptophan, and tyrosine are similar in shape. Therefore, based on these considerations, arginine, lysine, and histidine; alanine, glycine, and serine; and phenylalanine, tryptophan, and tyrosine can be considered biologically functional equivalents.
[0025] Amino acid exchanges in proteins that do not alter the overall activity of the molecule are well known in the art (H. Neurath, R.L. Hill, The Proteins, Academic Press, New York, 1979). The most common exchanges are between amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thr / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, and Asp / Gly.
[0026] Considering the mutations having the above-described biological equivalent activity, the amino acid sequence constituting the antibody of the present invention is interpreted to also include a sequence showing substantial identity with the sequence listed in the sequence listing. The substantial identity means a sequence showing at least 61% homology, in one specific example 70% homology, in another specific example 80% homology, and in yet another specific example 90% homology, when the sequence of the present invention and any other sequence are aligned to the greatest extent possible and the aligned sequence is analyzed using an algorithm commonly used in the art. Alignment methods for sequence comparison are known in the art. Various methods and algorithms for alignment are disclosed in Huang et al. Comp. Appl. BioSci. (1992) 8:155-65 and Pearson et al. Meth. Mol. Biol. (1994) 24:307-31, etc.
[0027] The term “IL-4” in this specification refers to a cytokine that induces differentiation of non-activated helper T cells (naive T cells, Th0 cells) into Th2 cells. IL-4 has various biological functions, such as stimulating activated B cells and T cells or differentiating B cells into plasma cells, and is an important regulator of humoral immunity and adaptive immunity.
[0028] The term “IL-4R” in this specification refers to the receptor for IL-4, which induces signal transduction related to the production of IgE antibodies by binding to the ligand IL-4. The receptor for IL-4 is generally known as IL-4Rα, and exists in the body in two types of complexes. The type 1 receptor generally exists as a complex of the γ chain (γc) and IL-4Rα, and is specific for IL-4. The type 2 receptor generally exists as a complex of IL-4Rα and IL-13Rα1, and is specific for both IL-4 and IL-13.
[0029] In this specification, the term “dupilumab” refers to a monoclonal antibody against IL-4Rα, product name DUPIXENT ® It is a commercialized antibody therapeutic agent. The mechanism of action of dupilumab is known to inhibit signal transduction by blocking the binding of IL-4 and IL-4Rα in the type 1 IL-4 receptor or by blocking the dimerization reaction of IL-4α and γ chain, and by blocking the dimerization reaction of IL-4Rα and IL-13Rα1 in the type 2 IL-4 receptor.
[0030] Antibodies of the present invention include, but are not limited to, monoclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, single-chain Fvs (scFV), single-chain antibodies, Fab fragments, F(ab') fragments, disulfide-linked Fvs (sdFV) and anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments and nanobodies (Nanobody or sybody) of the above antibodies.
[0031] The term “monoclonal antibody” as used herein means an antibody molecule of single molecular composition obtained from a substantially identical antibody population, wherein the monoclonal antibody exhibits single binding specificity and affinity for a specific epitope.
[0032] The term “nanobody” in this specification refers to a single-domain antibody analogue consisting of only one heavy chain variable region, and has the same meaning as “single-domain antibody (VHH antibody)” or “synthetic nanoantibody (sybody)” and can be used interchangeably. Nanobodies are the smallest antigen-binding fragments with full functionality, and can be constructed by first obtaining antibodies that naturally lack light and heavy chain constant regions 1 (CH1), and then cloning the variable region of the antibody heavy chain to construct single-domain antibodies (Variable Domain of Heavy-chain Antibodies, VHH) consisting of only one heavy chain variable region. Nanobodies can be manufactured by artificially processing antibody fragments extracted from camelids such as camels, llamas, and alpacas, and have the advantages of being strong against external environments such as temperature changes, easy to administer, and high production yield because they are about one-tenth the size of general antibodies.
[0033] In this specification, the term “E5R” refers to a mutation in which glutamic acid (E), the fifth amino acid in the sequence of SEQ ID NO: 1, is substituted with arginine (R).
[0034] In this specification, the term “A11Y” refers to a mutation in which the 11th amino acid in the sequence of SEQ ID NO: 1 is substituted from alanine (A) to tyrosine (Y).
[0035]
[0036] According to a specific embodiment of the present invention, the substitution of the 5th residue is a substitution with Arg, and the substitution of the 11th residue is a substitution with Tyr.
[0037]
[0038] According to a specific embodiment of the present invention, the anti-IL-4R antibody or antigen-binding fragment thereof of the present invention comprises at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.
[0039]
[0040] According to another aspect of the present invention, the present invention provides an anti-IL-4R antibody or antigen-binding fragment thereof comprising an amino acid sequence of SEQ ID NO: 5 comprising a substitution of at least one amino acid residue selected from the group consisting of residues 104 and 110.
[0041] According to the present invention, sequence number 5 is an amino acid sequence of a full-length nanobody comprising a CDR sequence represented by sequence number 1.
[0042] In this specification, the term “E104R” refers to a mutation in which glutamic acid (E), the 104th amino acid based on the sequence of SEQ ID NO: 5, is substituted with arginine (R).
[0043] In this specification, the term “A110Y” refers to a mutation in which the 110th amino acid in the sequence of SEQ ID NO: 5 is substituted from alanine (A) to tyrosine (Y).
[0044]
[0045] According to a specific embodiment of the present invention, the substitution of the 104th residue is a substitution with Arg, and the substitution of the 110th residue is a substitution with Tyr.
[0046]
[0047] According to a specific embodiment of the present invention, the anti-IL-4R antibody or antigen-binding fragment thereof of the present invention comprises SEQ ID NO: 5 and SEQ ID NO: 6.
[0048]
[0049] According to a specific embodiment of the present invention, the anti-IL-4R antibody or antigen-binding fragment thereof of the present invention comprises at least one amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.
[0050]
[0051] According to a specific embodiment of the present invention, the antigen-binding fragment of the present invention is composed of F(ab')2, Fab', Fab, Fv, scFv, and nanobody. More specifically, the antigen-binding fragment of the present invention is a nanobody.
[0052]
[0053] According to a specific embodiment of the present invention, the nanobody of the present invention has a convex scaffold structure.
[0054] The term “convex scaffold” used herein refers to the convex shape of a nanobody. The CDR-H3 of a nanobody is longer, consisting of an average of 19 amino acids, than the average of 12 amino acids of human CDR-H3, forming a convex loop that can effectively bind to concave active sites of enzymes or proteases. For example, scFv, one of the antigen-binding fragments, binds well to flat, linear epitopes, but nanobodies can also bind well to concave active sites. However, nanobodies can bind to flat active sites with high specificity, and this high affinity is known to be due to the flexible scaffold of the nanobody. Furthermore, nanobodies have the advantage of lower nonspecific background binding compared to scFv.
[0055]
[0056] According to another aspect of the present invention, the present invention provides an antibody or antigen-binding fragment in a dimer form comprising two identical or different antibodies or antigen-binding fragments selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7 and 8; and a linker.
[0057] The term “dimer antibody or antigen-binding fragment” as used herein means a bivalent nanobody in which two identical or different antibodies or antigen-binding fragments are linked.
[0058]
[0059] According to a specific embodiment of the present invention, the dimeric antibody of the present invention is composed of two antigens consisting of SEQ ID NO: 5 and a linker connecting them.
[0060] As used herein, the term "linker" essentially refers to a means for connecting two different fusion partners (e.g., biological polymers) using a covalent bond. The linker may be a peptide linker or a non-peptide linker. If the linker is a peptide linker, it may be composed of one or more amino acids.
[0061] As used herein, the term "peptide linker" refers to a linker composed of amino acids, specifically 1 to 60 amino acids, and more specifically 3 to 50 amino acids. However, the present invention is not limited thereto, and linkers of any length may be used as long as they do not interfere with the receptor binding ability of a bivalent nanobody. Meanwhile, the amino acids constituting the peptide linker may be of any type, and each peptide may be the same or different from each other. The peptide linker as used herein may specifically be an AAA linker.
[0062]
[0063] According to a specific embodiment of the present invention, the dimeric antibody of the present invention is composed of two antigens consisting of SEQ ID NO: 6 and a linker connecting them.
[0064] According to a specific embodiment of the present invention, the dimeric antibody of the present invention is composed of two antigens consisting of SEQ ID NO: 7 and a linker connecting them.
[0065] According to a specific embodiment of the present invention, the dimeric antibody of the present invention is composed of two antigens consisting of SEQ ID NO: 8 and a linker connecting them.
[0066]
[0067] According to a specific embodiment of the present invention, the linker of the present invention is composed of three amino acids. More specifically, the linker of the present invention is composed of SEQ ID NO: 9.
[0068]
[0069] According to another aspect of the present invention, the present invention provides a nucleic acid molecule encoding an antibody of the present invention or an antigen-binding fragment thereof.
[0070] As used herein, the term “nucleic acid molecule” has a comprehensive meaning including DNA (gDNA and cDNA) and RNA molecules, and nucleotides, which are the basic structural units of nucleic acid molecules, include not only natural nucleotides but also analogues in which sugar or base moieties are modified (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman et al., Chemical Reviews (1990) 90:543-584). The sequence of the nucleic acid molecule encoding the heavy chain, light chain variable region and nanobody of the present invention may be modified. The modifications include additions, deletions, or non-conservative or conservative substitutions of nucleotides.
[0071] The nucleic acid molecule of the present invention is also interpreted to include a nucleotide sequence that exhibits substantial identity with the nucleotide sequence described above. The substantial identity refers to a nucleotide sequence that exhibits at least 80% homology, in one specific example at least 90% homology, and in another specific example at least 95% homology, when the nucleotide sequence of the present invention is aligned with any other sequence to the greatest extent possible and the aligned sequence is analyzed using an algorithm commonly used in the art.
[0072] According to the present invention, the antibody of the present invention or an antigen-binding fragment thereof can be recombinantly obtained by expressing a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof in a host cell.
[0073] As used herein, the term “express” means artificially introducing a gene using a gene vector to cause a target cell to express an exogenous gene or to increase the natural expression level of an endogenous gene, thereby making the gene replicable as an extrachromosomal element or through chromosomal integration within the target cell. Therefore, the term “expression” has the same meaning as “transformation,” “transfection,” or “transduction.” More specifically, in the present invention, “express” means causing a target cell to artificially express an exogenous gene.
[0074] As used herein, the terms "gene carrier" or "gene delivery system" refer to any means of transporting a gene into a cell, and gene delivery is synonymous with transduction of the gene into the cell. At the tissue or cell level, gene delivery is synonymous with gene spread. Therefore, the gene delivery system of the present invention may be described as a gene penetration system or a gene spread system.
[0075] To prepare the gene delivery system of the present invention, the nucleotide sequence of the present invention is present in a suitable expression construct, and within the expression construct, the nucleotide sequence of the present invention can be operably linked to an expression control sequence. As used herein, the term “operably linked” means a functional linkage between a nucleic acid expression control sequence, such as a promoter, a signal sequence, or an array of transcription factor binding sites, and another nucleic acid sequence, whereby the expression control sequence regulates the transcription and / or translation of the other nucleic acid sequence.
[0076] The gene delivery system of the present invention can be produced in various forms, including (i) a naked recombinant DNA molecule, (ii) a plasmid, (iii) a viral vector, and (iv) a liposome or niosome containing the naked recombinant DNA molecule or plasmid.
[0077]
[0078] The nucleic acid molecule of the present invention may be used in the form of a gene therapy agent to deliver the antibody, antigen-binding fragment or nanobody of the present invention described above to a subject in the form of a gene, or may be used for the purpose of producing a protein pharmaceutical by recombinantly expressing a mutant antibody, antigen-binding fragment or nanobody from a host cell.
[0079] When mRNA is used as the nucleic acid molecule of the present invention, various modifications may be made, such as changing the length of the poly(A) tail or substituting some adenine bases; modifying the 5'cap; applying one or more modified nucleosides, in order to improve the expression (translation) efficiency of the antibody, antigen-binding fragment, or nanobody. Modified nucleosides that may be applied include, but are not limited to, N1-methylpseudouridine, pseudouridine, 2-thiouridine, 5-methyluridine, 5-methylcytidine, and 5-methoxyuridine, and any modified nucleoside known in the art to be capable of reducing the immunogenicity of the mRNA molecule may be applied. When the present invention is used as an mRNA therapeutic agent for the production of the antibody, antigen-binding fragment or nanobody of the present invention in the body of a patient, various lipid-based gene delivery systems (e.g., PEG-lipid, cholesterol, Ganglioside GM3, etc.) can be used for efficient delivery of mRNA molecules.
[0080] According to a specific embodiment of the present invention, the mRNA molecule used in the present invention has a 5'-UTR and a 3'-UTR bound to each of its two ends, and more specifically, a 5'-cap bound to the 5'-UTR. As used herein, the term "UTR (untranslated region)" refers to an untranslated region bound to each end of a coding sequence encoding a target protein in an mRNA, and there is a 5'-UTR present upstream of the coding sequence and a 3'-UTR present downstream. The term "5'-cap" refers to a component of an mRNA that is linked to the 5'-UTR and binds to eIF4E (eukaryote translation initiation factor 4E), thereby binding the 40S ribosomal subunit to the mRNA and initiating protein synthesis from the 5' start site of the mRNA, as well as protecting the mRNA from nucleases.
[0081] According to a more specific embodiment of the present invention, the mRNA molecule of the present invention additionally comprises a poly(A) tail comprising 20 to 400 bases at the 3' end.
[0082] As used herein, the term “poly(A) sequence”, “polyadenine sequence” or “poly(A) tail” refers to an adenine-repeated nucleotide sequence located at the 3' end of an RNA molecule that protects the RNA molecule from degradation by enzymes.
[0083]
[0084] According to another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating an inflammatory disease or an autoimmune disease, comprising, as an active ingredient, an antibody of the present invention or an antigen-binding fragment thereof; or a nucleic acid molecule encoding the same.
[0085] According to another aspect of the present invention, there is provided a method for preventing or treating an inflammatory disease or an autoimmune disease, comprising administering to a subject a pharmaceutical composition comprising, as an active ingredient, an antibody of the present invention or an antigen-binding fragment thereof; or a nucleic acid molecule encoding the same.
[0086] The term “prevention” as used herein means inhibiting the occurrence of a disease or condition in a subject who has not been diagnosed as having the disease or condition but is susceptible to such disease or condition.
[0087] As used herein, the term “treatment” means (a) suppressing the development of a disease, condition, or symptom; (b) alleviating the disease, condition, or symptom; or (c) eliminating the disease, condition, or symptom. When the composition of the present invention is administered to a subject, IL-4-mediated signaling is blocked, thereby suppressing the development of symptoms caused by an inflammatory disease or an autoimmune disease, eliminating them, or alleviating them. Therefore, the composition of the present invention may be a composition for treating these diseases on its own, or may be administered together with other pharmacological ingredients and used as an adjuvant treatment for the diseases. Accordingly, the terms “treatment” or “therapeutic agent” as used herein include the meaning of “adjuvant treatment” or “adjuvant treatment agent.”
[0088] In this specification, the term “inflammatory disease” is a general term for diseases whose main cause is an inflammatory response.
[0089] In this specification, the term “autoimmune disease” is a general term for all diseases caused by excessive or unwanted immune responses, and specifically, it refers to a disease caused by a process in which the induction or continuous maintenance of self-tolerance is not performed normally, resulting in an immune response to self-antigens and damage to one’s own tissues.
[0090]
[0091] According to a specific embodiment of the present invention, the inflammatory or autoimmune disease of the present invention is rhinitis, conjunctivitis, periodontitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, rheumatoid arthritis, polymyalgia rheumatica, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, periarthritis of the shoulder joint, tendinitis, tenosynovitis, peritendinitis, myositis, polymyositis, dermatomyositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, multiple sclerosis, inflammatory bowel disease, asthma, type 1 diabetes, psoriasis, eczema, scleroderma, vitiligo, peripheral neuritis, uveitis, autoimmune cytopenia, autoimmune myocarditis, atopic dermatitis, primary cirrhosis, dry eye, Selected from the group consisting of Goodfeiter syndrome, autoimmune meningitis, Addison's disease, autoimmune parotitis, dystrophic epidermolysis bullosa, epididymitis, glomerulonephritis, Graves' disease, celiac disease, Guillain-Barré syndrome, Hashimoto's disease, hemolytic anemia, myasthenia gravis, amyotrophic lateral sclerosis, pemphigus vulgaris, sarcoidosis, spondyloarthropathy, thyroiditis, vasculitis, myxedema, pernicious anemia, antiphospholipid syndrome, and graft-versus-host disease.
[0092]
[0093] According to a specific embodiment of the present invention, the rhinitis of the present invention is nasal polyps or sinusitis.
[0094] The term “nasal polyp” in this specification generally refers to a pathological condition in which a grape-shaped benign edematous mucosa originating from the middle meatus (middle nasal passage) protrudes into the nasal cavity.
[0095] The term “sinusitis” in this specification refers to a disease in which the natural openings called paranasal sinuses in the facial bones around the nose are blocked, preventing proper ventilation and drainage of the paranasal sinuses, causing secondary inflammation in the paranasal sinuses, and the inflammation worsens as purulent secretions accumulate.
[0096]
[0097] According to a specific embodiment of the present invention, the sinusitis of the present invention is chronic sinusitis (CRS).
[0098] The term “chronic sinusitis” as used herein generally refers to cases where symptoms of sinusitis persist for a long period of time, typically about 3 months or more, but is not limited thereto and includes all cases where symptoms persist beyond the normal recovery period of the disease.
[0099]
[0100] According to a specific embodiment of the present invention, the chronic sinusitis of the present invention is chronic sinusitis with nasal polyp (CRS with nasal polyp, CRSwNP).
[0101] In this specification, the term “chronic sinusitis with nasal polyp (CRSwNP)” refers to a disease in which nasal polyps (nasal polyps) appear along with chronic sinusitis, and in contrast, a case in which nasal polyps are not present is referred to as “chronic sinusitis without nasal polyp (CRSsNP).”
[0102]
[0103] According to a specific embodiment of the present invention, the composition of the present invention is a composition for nasal administration.
[0104] The term “nasal administration” in this specification means a method of administering a drug through the nasal cavity or the mucous membrane of the nasal cavity, and the above-mentioned method of administration may be by a non-invasive route.
[0105]
[0106] The features and advantages of the present invention are summarized as follows:
[0107] (a) The present invention provides an antigen-binding fragment, specifically a nanobody, which has a remarkable binding affinity to the anti-IL-4 receptor and effectively blocks signal transduction by IL-4, while being able to directly penetrate epithelial cells due to its low molecular weight.
[0108] (b) Furthermore, the inventors of the present invention discovered amino acid substitution variants and their bivalent forms that can maximize the IL-4 receptor binding affinity of the nanobody, and confirmed their excellent nasal epithelial cell permeability and remarkable inflammatory response therapeutic effect.
[0109] (c) Accordingly, the present invention can be usefully used as a composition for treating chronic inflammatory diseases, particularly as a nasal spray composition, which excludes various side effects caused by systemic administration.
[0110]
[0111] Figure 1 shows the final process of anti-IL-4R nanobody screening, where the Y-axis represents the fold-change of OD values for IL-4R and MBP, indicating the IL-4R specificity of each nanobody clone, and the clones marked with red boxes represent the finally selected nanobodies with fold-change values higher than the threshold (1.7).
[0112] Figure 2 illustrates the results of purifying each nanobody and examining the same concentration of nanobody through ELISA to confirm the binding affinity for the IL-4R molecule for the four final nanobody candidates. It was found that the H5 nanobody had the highest binding affinity for the IL-4R molecule among the four candidates at the same concentration.
[0113] Figure 3 shows the results of selecting three nanobody candidates based on the ELISA results and examining whether the binding affinity is related to the IL-4 signal blocking function. The degree of signal blocking of each nanobody was compared with that of dupilumab at three different concentrations. Reporter cells were incubated with 83 pM IL-4 and each nanobody (or antibody) for 24 hours, and the results showed that dupilumab and H5 nanobody had the most effective IL-4 signal blocking effect among the candidates.
[0114] Figure 4 is a diagram illustrating the results of comparing the signal blocking effect of the H5 nanobody selected as the final IL-4R blocking nanobody with that of dupilumab at three different concentrations.
[0115] Figure 5 is a drawing showing the results of evaluating the binding affinity of dupilumab and H5 nanobody to HEK293 cells using a plate reader.
[0116] Figures 6a to 6d are drawings showing the results of immunofluorescence staining and image analysis for the regulation of FOXJ1 expression by IL-4, dupilumab, and nanobody.
[0117] Figure 7 is a drawing showing the structure of H5 of the present invention using the Alphafold Ⅱ program.
[0118] Figure 8 is a drawing showing the results of analyzing the affinity of H5 and its substitution mutants, H5 A110Y and H5 E104R, for receptors using the surface plasmon resonance (SPR) method.
[0119] Figure 9a is a diagram illustrating the results of analyzing the cell binding affinity of H5 and its substitution mutants, H5 A110Y and H5 E104R. Figure 9b is a diagram illustrating the results of analyzing the binding affinity of H5 and its substitution mutants, H5 A110Y and H5 E104R, to the IL-4 receptor using a reporter assay. Figure 9c is a diagram illustrating the results of analyzing the binding affinity of H5 and its substitution mutants, H5 A110Y and H5 E104R, to the IL-3 receptor using a reporter assay.
[0120] Figure 10 is a drawing showing the structure of a bivalent nanobody, which is a dimer type nanobody of the present invention, using the Alphafold Ⅱ program.
[0121] Figure 11 is a drawing showing the results of analyzing the affinity of a bivalent nanobody composed of two H5 WTs, a bivalent nanobody composed of two A110Y substitution mutants of H5, and a bivalent nanobody composed of two E104R substitution mutants of H5 for receptors using the surface plasmon resonance (SPR) method.
[0122] FIG. 12a is a diagram showing the results of a cell binding assay of H5 and its substitution mutants H5 A110Y and H5 E104R, and the bivalent nanobody of the present invention. FIG. 12b is a diagram showing the results of a reporter assay for the IL-4 receptor blocking ability of H5 and its substitution mutants H5 A110Y and H5 E104R, and the bivalent nanobody of the present invention. FIG. 12c is a diagram showing the results of a reporter assay for the IL-13 receptor blocking ability of H5 and its substitution mutants H5 A110Y and H5 E104R, and the bivalent nanobody of the present invention.
[0123] Figure 13 is a drawing illustrating an air-liquid interface culture method for confirming the degree of penetration of the nanobody of the present invention through nasal epithelial cells and the effect of preventing or treating inflammation.
[0124] Figures 14a and 14b are drawings showing the results of analyzing the mRNA levels of IL-4 / IL-13 inflammatory signaling markers (MUC5AC, CCL26, and FOXJ1) using qPCR after injecting different concentrations of H5 nanobodies into air-liquid interface culture.
[0125] Figure 15 is a drawing showing the results of analyzing the expression level of the IL-4 / IL-13 inflammatory signal marker (MUC5AC) through immunostaining after injecting different concentrations of H5 nanobody into air-liquid interface culture.
[0126] Figure 16 is a drawing showing the results of Western blotting (WB) of the lower cell culture after treating the upper part of the nasal epithelium with a substance in an air-liquid interface culture.
[0127] Figure 17 is a diagram illustrating the results of analyzing the paracellular permeability of a bivalent nanobody composed of two H5s, H5, and dupilumab.
[0128] Figure 18 is a drawing showing the results of analyzing the mRNA expression levels of tight junction proteins Zo-1 and Occludin in nasal epithelium treated with IL-4 / IL-13.
[0129]
[0130] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.
[0131]
[0132] Example
[0133] Experimental and analytical methods
[0134] cell
[0135] HEK293T and HEK293 cell lines were purchased from the Korea Cell Line Bank. These cells were cultured in DMEM high-glucose medium (Gibco, 11995-065) supplemented with 10% fetal bovine serum (FBS) (Gibco, 26140-079) and penicillin / streptomycin (Gibco, 15140-122) at 37°C in an incubator with 5% CO2.
[0136]
[0137] Sequence of primers used
[0138] Primer information was referenced from a paper on the production of synthetic nanobodies (Zimmermann et al., 2018). 1 .
[0139]
[0140] FW_c_for: CAA GTC CAG CTG GTG GAA TCG (SEQ ID NO: 10)
[0141] FW_c_rev: GCC GCT AGC CGC ACA G (SEQ ID NO: 11)
[0142]
[0143] Link2_c_for: ATA TAT GAA GAC CTC TGC GCG GC (SEQ ID NO: 12)
[0144] Link2_c_rev: ATG CAT GGT CTC AGC AGT AAT ACA AAG CAG TAT CTT CCG G (SEQ ID NO: 13)
[0145] CDR3_c: GAA GAC CTC TGC GCG GCA GCC 111 111 GGC 111 111 111 CCG CTG 111 111 111 111 TAT 222 TAC TGG GGT CAG GGC ACC CAA GTT ACC GTT TCT (SEQ ID NO: 14)
[0146] 5'_flank_for : CGA AAT TAA TAC GAC TCA CTA TAG GGA GAC (SEQ ID NO: 15)
[0147]
[0148] 5'_flank_rev: TAT AGC TCT TCA ACT ACC CAT GGA TAT ATC TCC (SEQ ID NO: 16)
[0149] 3'_flank_for: TAT AGC TCT TCT GCA AAG CTT TAT ATG GCC TC (SEQ ID NO: 17)
[0150] tolAK_rev: CCG CAC ACC AGT AAG GTG TGC GGT TTC AGT TGC CGC TTT CTT TCT (SEQ ID NO: 18)
[0151] RT primer: CTT CAG TTG CCG CTT TCT TTC TTG (SEQ ID NO: 19)
[0152] Long_FX_for: ATA TGC TCT TCT AGT CAA GTC CAG CTG GTG GAA TCG (SEQ ID NO: 20)
[0153] Long_FX_rev: TAT AGC TCT TCA TGC AGA AAC GGT AAC TTG GGT GCC C (SEQ ID NO: 21)
[0154] qPCR_RD_5'_for: GGG AGA CCA CAA CGG TTT CCC (SEQ ID NO: 22)
[0155] qPCR_ RD_L_5_rev: GCC GCT AGC CGC ACA GCT C (SEQ ID NO: 23)
[0156]
[0157] Construction of a random convex scaffold DNA library
[0158] pRDV (Addgene, 132696) containing Sb-convex was selected as a template for PCR. The FW_c_for and Link2_c_rev primers were used to amplify the former region of the convex scaffold, which includes the CDR1 and CDR2 regions. The Link2_c_for, FW_c_rev, and CDR3_c primers were used to amplify the latter region of the convex scaffold by randomizing the CDR3 region. The random primer CDR3_c contains 10 different trinucleotide residues, 9 of which (111) are rich in A, S, T, N, and Y (10.6% each), D, E, Q, R, K, H, and W (5% each), and are characterized by a low abundance of the nonpolar amino acids F, M, V, I, L, and G (2% each). 1 . Another trinucleotide residue (222) lacks amino acids D and A, because the two amino acids mentioned above are underrepresented at the ends of the β-sheet. 2 . BbsI restriction sites are present at both ends of the former (scaffold) and latter (randomized) convex fragments, which are restricted and ligated to form 3.17×10 12 A convex library with a variety of features was formed.
[0159]
[0160] In vitro transcription
[0161] The 5' and 3' regions of the CD3-randomized convex library were flanked before transcription. The 5' and 3' flanking regions were amplified from plasmid pRDV5 containing Sb-convex (Addgene, 132696) using the primers 5'_flank_for and 5'_flank_rev; and the primers 3'_flank_for and tolAK_rev; respectively. The flanking regions were restricted with BspQI and then ligated to each end of the library. The library with the flanking regions was transcribed using the T7 Ribomax RNA Production System (Promega, P1320) according to the manual.
[0162]
[0163] Ribosome display
[0164] Ribosome display can be done with minimal effort, about 10 12 It can provide the advantage of being able to display different library members. 1 However, this method has not been widely applied due to several reasons related to reagents and unfavorable RNase activity. 3 To overcome technical obstacles, the in vitro translation kit PUREfrex2.1 (GeneFrontier, PF213-0.25-EX) was adopted. 1 . The kit lacks oxidized glutathione (GSSG) and disulfide bridge isomerase (DsbC), which are additionally supported to form disulfide bond folding. 70 ng of RNA library (approximately 1.7 × 10 12Molecules) were used as input, and the experimental procedure followed the manual. In vitro translation reaction was performed at 37°C for 1 hour to form ribosome complexes. Before ribosome display, 12 μl of Dynabeads™MyOne™StreptavidinT1 beads (Invitrogen, 65601) were washed twice with 0.5% WTB-BSA buffer (50 mM Tris / acetate pH 7.4, 150 mM NaCl, 50 mM MgAc2, supplemented with BSA). The magnetic beads were then blocked with WTB-BSA buffer for more than 20 minutes. The ribosomal complex was added to 100 μl of panning solution (WTB-D-BSA (WTB-BSA with 0.1% tween20) supplemented with 500 μg heparin and 1 μl RNaseIn (Promega N2611)), and the mixture was centrifuged at 20,000 × g for 5 min. The supernatant was mixed with biotinylated IL-4R (Acro Biosystems, ILR-H82E9) and incubated on ice for 2 h. The magnetic beads were washed three times with WTB-B-BSA, and the panning-IL-4R mixture was added to the beads and incubated on ice for 1 h. The entire mixture was then washed three times with WTB-D (50 mM Tris / acetate pH 7.4, 150 mM NaCl, 50 mM MgAc2, supplemented with 0.1% Tween 20). The supernatant was purified using the RNeasy kit (Qiagen, 74004) with a 15 μl elution volume.
[0165]
[0166] Reverse transcription
[0167] RNA eluted from the ribosome display was reverse transcribed using SuperiorScript III reverse transcriptase (Enzynomics, RT006M) in a total volume of 30 μl according to the manual. The resulting cDNA was purified using a 30 μl elution volume of a PCR purification mini kit (Favorgen, FAGCK 001-1). The resulting cDNA was purified using a 30 μl elution volume of a PCR purification mini kit (Favorgen, FAGCK 001-1). 1 μl of the elution was used as a template for qPCR analysis, and 29 μl of the elution was used for amplification. The purified DNA in the form of the resulting cDNA was amplified by PCR using the Long_FX_for and Long_FX_rev primers. The total reaction volume was 100 μl, and the reaction was divided into two tubes at the end.
[0168]
[0169] qPCR
[0170] qPCR analysis was used to assess the quality of cDNA resulting from ribosome display and phage display selections and to monitor library enrichment during the selection step. 4 . For the experiment, a QuantStudio 3 Real-time PCR instrument (Applied Biosystems) was used with AccuPower® 2X Greenstar qPCR Master Mix (Bioneer, K-6251). The PCR program conditions were as follows: 95°C, 2 min (initial denaturation) / 95°C, 10 s; 63°C, 30 s (denaturation, annealing, extension, measurement) / The melting curve step followed the default settings in the instrument manual.
[0171]
[0172] electroporation
[0173] FX Cloning 5The enriched nanobody library was introduced into the phagemid vector pDXinit (Addgene, 110101) using . 350 μl of E. coli SS320 (Lucigen, 60512-1) was thawed on ice, and 50 μl of the phagemid ligation mix containing the enriched library was added to an electroporation cuvette (Biorad, 1652086) containing SS320 and mixed by gentle pipetting. The cell mixture was pulsed using a Biorad Gene Pulser II electroporation system using 2.4 kV, 25 μF, and 300 Ω. The electroporated cells were immediately transferred to 25 ml of SOC medium and incubated at 37°C, 160 rpm for 30 min. Subsequently, the recovered culture was transferred to 225 ml of 2TY medium supplemented with 200 ug / ml ampicillin and 2% glucose and incubated overnight at 37°C, 160 rpm.
[0174]
[0175] Production and purification of phages
[0176] 1 ml of electroporated pre-culture was added to 50 ml of 2YT medium (supplemented with 200 ug / ml ampicillin and 2% glucose) and then OD 600 = 0.6, and cultured at 37°C, 160 rpm. Then, 10 ml of the culture was mixed with 30 μl of M13KO7 helper phage (NEB, N0315S) and cultured without shaking at 37°C for 1 h. The incubated culture was centrifuged at 5,000 × g for 10 min, and the supernatant was removed. The pellet was resuspended in 50 ml of 2YT medium (supplemented with 200 μg / ml ampicillin and 25 μg / ml kanamycin) and incubated overnight at 37°C, 160 rpm.
[0177] The overnight culture was centrifuged at 6,000 × g at 4° C. for 30 minutes. 40 ml of the supernatant was transferred to a new 50-ml tube, 10 ml of PEG6000 / NaCl was added, and the tube was inverted approximately five times. The mixture was incubated on ice overnight and then centrifuged at 10,000 × g at 4° C. for 1 hour. After removing the supernatant, the tube was gently washed with 40 ml of PBS and then resuspended in 1 ml of PBS. The resuspended phage was centrifuged at 20,000 × g at 4° C. for 5 minutes, and the supernatant was collected in a new tube. The titer of the collected phage was measured at 269 nm and 320 nm using a UV-visible spectroscopy and calculated using the following equation:
[0178]
[0179]
[0180] Phage display
[0181] E. coli SS320 was cultured in 50 ml of 2YT medium (supplemented with 10 ug / ml tetracycline) and half of a 96-well plate was coated with 100 ul of 67 nM neutravidin at 4°C one day before phage display.
[0182] - First round of phage display
[0183] Neutravidin-coated plates were washed with 250 μl of TBS per well and blocked with 250 μl of TBS-BSA (TBS supplemented with 0.5% BSA). Biotinylated IL-4R was added to 4.9 ml of purified phage (1012 phages / ml) to a protein concentration of 50 nM and incubated on ice for 2 h. Neutravidin-coated plates were washed with 250 μl of TBS-BSA-D (TBS supplemented with 0.5% BSA and 0.1% Tween 20). 100 μl of the phage-IL-4R mixture was added to each well of the plate and incubated on ice for 1 h. Each well of the plate was washed three times with 150 μl of TBS-D (TBS supplemented with 0.1% Tween 20), and the plates were dried on paper towels for 2 min after each wash step. 100 μl of PD elution buffer (TBS with 0.25 μg / ml trypsin added as powder) was added to each well, and the plate was incubated at room temperature for 10 minutes. The eluted solution was transferred to a new tube, and 40 μl of AEBSF solution (Merck, A8456) was added to the tube. 1 μl of the sample was analyzed by qPCR, and the remaining sample was added to 50 ml of cultured SS320. The mixture was incubated without shaking at 37°C for 1.5 hours, after which 50 ml of the mixture was transferred to 200 ml of 2YT medium (supplemented with 200 μg / ml ampicillin and 2% glucose) and incubated overnight at 37°C and 160 rpm.
[0184] - Second round of phage display
[0185] Phages generated from the primary phage display were cultured in TBS-BSA-D (5 × 10 12phages / ml) were harvested and purified. Biotinylated IL-4R was added to 100 μl of 50 nM phage solution and incubated on ice for 2 h. 12 μl of Dynabeads™MyOne™StreptavidinC1 beads (Invitrogen, 65001) were washed twice with 500 μl of TBS-WTB-BSA and then blocked with 500 μl of WTB-BSA on ice for more than 20 min. The magnetic beads were washed three times with 500 μl of TBS-BSA-D, resuspended, and incubated with the phage-IL-4R complex solution on ice for 1 h. After incubation, the mixture was washed with 500 μl of TBS-BSA-D and then resuspended in 100 μl of 'competition buffer', TBS-BSA-D supplemented with 5 μM non-biotinylated IL-4R (Sino Biological, 10402-H08H), and incubated on ice for 3 min. The competitive non-biotinylated IL-4R was washed twice with 500 μl of TBS-D. The beads were resuspended in 100 μl of PD elution buffer and incubated at room temperature for 10 min. 0.8 μl of ABESF was added to the resulting solution, mixed by pipetting, and 1 μl of the solution was used for qPCR analysis, and the remaining solution was used for infection of SS320. E. coli SS320 was cultured overnight at 37°C, 160 rpm in 2YT medium supplemented with 200 ug / ml ampicillin and 2% glucose.
[0186]
[0187] Production and purification of biotinylated MBP
[0188] Plasmid pBXNH3CA_MBP (addgene, 132700) was transformed into Escherichia coli BL21 for expression. The culture was cultured in TB medium supplemented with 100 μg / ml ampicillin at 37°C and 160 rpm for 4 h. Arabinose and biotin were added at concentrations of 0.02% and 100 μM, respectively, for expression and biotinylation. The culture was then incubated overnight at 22°C and 160 rpm for expression. The overnight culture was sonicated and then labeled with MBP MiniExcellose. ® (Takara, AEx-MC-M03) was used for purification.
[0189]
[0190] enzyme-linked immunosorbent assay (ELISA)
[0191] Using the FX cloning method, the enriched library was cloned into the pSBinit vector (addgene, 110100) through phage display twice. 5 The cloned plasmid was transformed into E. coli SS320 via electroporation, cultured overnight at 37°C and 160 rpm, and the plasmid was extracted. The extracted plasmid was transformed into E. coli BL21 (Enzynomics, CP110), plated on LB-agar plates supplemented with 25 ug / ml chloramphenicol, and incubated overnight at 37°C.
[0192] 1.2 ml of TB medium supplemented with 25 ug / ml chloramphenicol was prepared in each well of a 96-well deep-well plate labeled 'preculture'. Ninety-five colonies were selected from the incubated plate, and each colony was inoculated into each well, and the first well was filled with the positive control pSb_init containing the MBP nanobody Sb_MBP#1 (addgene, 132699). The deep-well plate was gas-permeably sealed and grown at 37°C, 300 rpm for 4 h. A new 96-well deep-well plate filled with 1 ml of pre-warmed TB medium supplemented with 25 ug / ml chloramphenicol was labeled 'expression culture'. 50 ul of 'preculture' was added to the corresponding well of the expression culture, and the plate was monitored to OD 600= 0.4~0.8, incubated at 37℃, 300 rpm for 2 hours, then at 22℃, 300 rpm. After sufficient growth, expression was induced by adding 0.02% (wt / vol) L-(+)-arabinose, and incubated overnight at 22℃, 150 rpm. The next day, cells were collected by centrifugation at 5,000xg, 4℃ for 15 minutes. The pallet of 'preculture' was stored at -20℃ for DNA purification, and the pallet of 'expression culture' was resuspended with 100 ul of periplasmic extraction buffer (20% sucrose, 50 mM Tris pH 8.0, 0.5 mM EDTA, and 0.5 ug / ml lysozyme (denoted as DW)) by intensive vortexing. After incubation on ice for 30 minutes, 900 μl of TBS containing 1 mM MgCl2 was added to each well. The plates were centrifuged at 5,000 × g at 4°C for 15 minutes, and the supernatant was used as periplasmic extraction for ELISA. Two 96-well immunoplates were coated with 100 μl of 5 μg / ml protein A solution and incubated overnight at 4°C with adhesive sealing. The plates were washed with 250 μl of TBS per well and then blocked with 150 μl of TBS-BSA per well. Then, 100 μl of anti-c-Myc antibody (Biolegend, 626802) diluted 1:2,000 in TBS-BSA-D was added per well and incubated for 20 minutes. After washing three times with 250 ul of TBS-D, 80 ul of TBS-BSA-D was added to each well to compare nanobody binding between IL-4R, and 20 ul of the same peripheral cytoplasmic extract was added in parallel to compare the degree of nanobody binding to IL-4R and MBP, and incubated for 20 minutes.The plate was washed with 250 μl of TBS-D per well, 100 μl of 50 nM MBP was added to the first two wells, and 100 μl of 50 nM biotinylated IL-4R was added to each well, and the plate was incubated for 20 minutes. After washing three times with 250 μl of TBS-D, 100 μl of 1:5,000 streptavidin-peroxidase (Invitrogen, 434323) diluted in TBS-BSA-D was added to each well and incubated for 20 minutes. The plate was washed again three times with TBS-D, and 100 μl of TMB substrate (biolegend, 421101) was added to each well. The reaction took approximately 15 minutes until individual wells turned blue. The absorbance was measured at 650 nm using a plate reader.
[0193]
[0194] Production and purification of nanobodies
[0195] Nanobody clones in the expression vector (pSBinit) were transformed into E. coli BL21 and cultured overnight at 37°C and 160 rpm. 2 ml of the overnight culture was inoculated into 200 ml of TB medium supplemented with 25 ug / ml of chloramphenicol, and OD 600 = 0.6, the culture was incubated at 37°C, 200 rpm, and then moved to 22°C, 150 rpm for 1 hour. To induce expression, 0.02% arabinose was added and incubated overnight at 37°C, 150 rpm. The overnight culture was centrifuged at 5,000×g, 4°C for 15 minutes, and the pellet was resuspended in 20 ml of periplasmic extraction buffer on ice for 30 minutes. After incubation, 180 ml of TBS containing 1 mM MgCl2 was added, and centrifuged at 5,000×g, 4°C for 15 minutes.
[0196] 1 ml of TALON®Superflow™ (Cytiva, 28957502) slurry was pre-equilibrated with Tris-buffered saline (TBS), pH 8.0. After binding, the beads were washed three times with wash buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 5 mM imidazole), and the nanobodies were eluted with elution buffer (50 nM Tris, pH 8.0, 300 mM NaCl, 200 mM imidazole). The eluted nanobodies were buffer-exchanged overnight using a Slide-A-Lyzer® Dialysis Cassette (Thermo, 66330).
[0197]
[0198] STAT6-luciferase reporter system for measuring IL-4R inhibition
[0199] HEK293 cell lines were transduced to stably express human STAT6 (addgene, 81950) via a puromycin-resistant lentivirus system, and luciferase (addgene, 35554) induced by pSTAT6 via a blasticidin-resistant system, thereby enabling stable expression of luciferase under the control of the STAT6 response to IL-4 signaling. 6,7 . 5 x 10 4 Reporter cells were seeded into each well of a 96-well cell culture plate and cultured with dupilumab or one of the nanobodies in hIL-4 and serum-free RMPI medium at 37°C and 5% CO2 for 24 h. The cell lysates were transferred to a white 96-well plate, and 50 μl of luciferase substrate (Promega, E1501) was added. Random luminescence units were measured using a SpectraMax®M5 luminometer (Molecular Devices).
[0200]
[0201] Immunofluorescence staining and image analysis
[0202] HNE cells in transwells were washed with PBS and fixed with 500 μl of 4% paraformaldehyde (Biosesang, P2031) for 30 min at room temperature. The HNE cells were then incubated with 100 μl (1:200) of FOXJ1 primary antibody (GeneTex, GTX114408) for 1 h, followed by 100 μl (1:1000) of mouse anti-rabbit FITC for 30 min, and then washed three times with PBS. The cells were photographed on a Zeiss LSM 700 using parameter settings of 405 and 488 nm lasers, and the Z-stack multidimensional acquisition function was applied. Z-stack slice images were acquired with an interval of 8 μm.
[0203]
[0204] In-silico affinity maturation
[0205] After predicting the structure of the nanobody using AI-based structural prediction, we identified its receptor binding structure. Using this identified receptor binding structure and a computer-based binding enhancement technique, we identified two substitution mutations, H5 A110Y and H5 E104R, which can enhance receptor binding. The affinity of the identified H5 mutants was analyzed using surface plasmon resonance (SPR).
[0206]
[0207] Cell Surface Antigen Binding & Reporter Cell Assay
[0208] The cell binding affinity of H5 nanobody and mutant H5 was analyzed through cell surface antigen binding assay, and the IL-4 and IL-13 receptor blocking abilities were analyzed through IL-4 and IL-13 reporter assays, respectively.
[0209] Experiments to evaluate receptor blocking ability were performed as follows: A reporter cell line was created by inserting the STAT6 gene and the luciferase gene that can be expressed by phosphorylated-STAT6 into HEK293 cells using lentivirus. 5 x 10 4 Reporter cells were treated with IL-4 / IL-13 and nanobodies in 96-well plates and incubated at 37°C in 5% CO2 for 24 h. After removing all the culture medium, 20 μl of lysis buffer (25 mM Tris pH 8.0, 4 mM EGTA, 10% glycerol, and 10 μl of Triton X-100 in 1 ml of DW) was added, and then 50 μl of luciferin substrate was added to measure luminescence.
[0210]
[0211] Bivalent Nanobody
[0212] To maximize the receptor blocking ability of the nanobody of the present invention, a bivalent nanobody in the form of a dimer was prepared by connecting H5 or its substituted mutant nanobody with a peptide linker. The receptor affinity of the prepared bivalent nanobody was analyzed through surface plasmon resonance (SPR). In addition, the cell binding ability of the prepared bivalent nanobody was analyzed through a cell surface antigen binding assay, and the IL-4 and IL-13 receptor blocking abilities were analyzed through IL-4 and IL-13 reporter assays, respectively.
[0213] In this specification, an AAA peptide linker is used as an implementation example.
[0214] AAA (SEQ ID NO: 9)
[0215]
[0216] Air-Liquid Interface Culture
[0217] To confirm the nasal cell penetration efficiency and inflammation prevention or treatment effect of the nanobody or divalent nanobody developed in the present invention, an air-liquid interface culture was prepared. The air-liquid interface culture was prepared by culturing human nasal epithelial cells on top of a micro-pore membrane, which is a permeable membrane, and positioning an air layer on top of the nasal cells and a liquid culture medium on the bottom of the nasal cells.
[0218] Air-liquid interface (ALI) cultures were performed as follows: Human nasal epithelial cells were obtained from rhinitis / nasal polyp patients, and primary nasal epithelial cells from the second passage were cultured in a medium containing basal epithelial growth medium using transwell plates. After 3 days of submerged culture, the upper portion of the medium was removed to perform air-liquid interface (ALI) culture. After 2 weeks of ALI culture, fully differentiated nasal epithelial cells were used for experiments.
[0219] The receptor blocking ability and anti-inflammatory effects of H5 were confirmed ex vivo using air-liquid interface culture. MUC5AC, CCl26, and FOXJ1 were used as markers of inflammation.
[0220] In addition, after treating the material on the upper side of the nasal epithelial cells in the air-liquid interface culture, Western blotting was performed on the cell culture medium at the bottom to confirm the cell permeability.
[0221]
[0222] Analysis of tight junction proteins in nasal epithelial cells
[0223] After treating nasal epithelial cells with IL-4 / IL-13, the expression levels of tight junction proteins Zo-1 and Occuldin were measured, and changes in cell permeability were measured when an inflammatory response occurred due to IL-4 / IL-13.
[0224]
[0225] Sequence of nanobody candidates
[0226] H5 CDR sequence (SEQ ID NO: 1): DKGREYTLARAKYWYW
[0227] H5 CDR sequence, E5R mutation (SEQ ID NO: 2): DKGRRYTLARAKYWYW
[0228] H5 CDR sequence, A11Y mutation (SEQ ID NO: 3): DKGREYTLARYKYWYW
[0229] H5 CDR sequence, E5R + A11Y mutation (SEQ ID NO: 4) DKGRRYTLARYKYWYW
[0230] H5 full-length sequence (SEQ ID NO: 5):
[0231] QVQLVESGGGSVQAGGSLRLSCAASGSISSITYLGWFRQAPGKEREGVAALSTSSGTTYYADSVKGRFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAADKGREYTLARAKYWYWGQGTQVTVSAGRAGEQKLISEEDLNSAVDHHHHHH
[0232] H5 full-length sequence, E104R mutation (SEQ ID NO: 6):
[0233] QVQLVESGGGSVQAGGSLRLSCAASGSISSITYLGWFRQAPGKEREGVAALSTSSGTTYYADSVKGRFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAADKGRRYTLARAKYWYWGQGTQVTVSAGRAGEQKLISEEDLNSAVDHHHHHH
[0234]
[0235] *H5 full-length sequence, A110Y mutation (SEQ ID NO: 7):
[0236] QVQLVESGGGSVQAGGSLRLSCAASGSISSITYLGWFRQAPGKEREGVAALSTSSGTTYYADSVKGRFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAADKGREYTLARYKYWYWGQGTQVTVSAGRAGEQKLISEEDLNSAVDHHHHHH
[0237] H5 full-length sequence, E104R + A110Y mutation (SEQ ID NO: 8):
[0238] QVQLVESGGGSVQAGGSLRLSCAASGSISSITYLGWFRQAPGKEREGVAALSTSSGTTYYADSVKGRFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAADKGRRYTLARYKYWYWGQGTQVTVSAGRAGEQKLISEEDLNSAVDHHHHHH
[0239]
[0240] Experimental results
[0241] Final steps in anti-IL-4R nanobody screening
[0242] After ribosome display and two rounds of phage display, approximately 102 nanobody clones were screened. To enrich this pool of nanobodies, ELISA was performed for IL-4R and MBP. The y-axis of the graph represents the fold change in OD values for IL-4R and MBP, indicating the specificity of each nanobody clone for IL-4R. Clones marked in red boxes are the final nanobodies selected with fold changes higher than the threshold (1.7). Excluding overlapping sequences, the inventors ultimately obtained four different nanobody sequences: H5, G5, E9, and B3 (Figure 1).
[0243]
[0244] *Binding affinity of nanobody candidates for IL-4R
[0245] Four final nanobody candidates targeting the IL-4R were selected through ribosome display, phage display, and ELISA. Each nanobody was purified and tested by ELISA to determine its binding affinity for the IL-4R molecule at the same concentration. The results showed that the H5 nanobody had the highest binding affinity for the IL-4R molecule among the four candidates at the same concentration (Fig. 2).
[0246]
[0247] IL-4 signal blocking activity of nanobody candidates
[0248] Three nanobody candidates were selected based on previous ELISA results, and their binding affinities were examined to determine whether they correlated with IL-4 signal blocking activity. The signal blocking activity of each nanobody at three different concentrations was compared with that of dupilumab. Reporter cells were incubated with 83 pM IL-4 and each nanobody (or antibody) for 24 hours. The results confirmed that dupilumab and the H5 nanobody were the most effective IL-4 signal blockers among the candidates (Fig. 3).
[0249]
[0250] Comparison of the IL-4 signaling blocking activity of dupilumab and H5
[0251] Based on previous results, the H5 nanobody was selected as the final IL-4R blocking nanobody. The signal blocking activity of each nanobody was compared with dupilumab at three different concentrations. Reporter cells were incubated with 667 pM IL-4 and the nanobody (or antibody) for 24 hours. The H5 nanobody was found to exhibit blocking activity similar to dupilumab at approximately twice the concentration (Fig. 4).
[0252]
[0253] Comparison of cell binding affinities of dupilumab and H5
[0254] The binding affinity of dupilumab and the H5 nanobody for HEK293 cells was assessed using a plate reader. Anti-human IgG-FITC was used as the secondary antibody for dupilumab, and anti-Myc-FITC was used as the secondary antibody for the H5 nanobody. The fluorescence units of each antibody (nanobody) were normalized to the fluorescence units of the respective secondary antibodies. The results in Figures 4 and 5 suggest that the signal blocking activity depends on the binding of the antibody (nanobody) to the cells.
[0255]
[0256] Regulation of FOXJ1 expression by IL-4, dupilumab, and nanobodies (Figure 6)
[0257] FOXJ1 is a forkhead box family transcription factor whose expression is suppressed by IL-4 / IL-13 signaling and STAT6 phosphorylation. Figure 6a is an orthogonal image of human nasal epithelial cells (HNE) treated with IL-4, dupilumab, and the H5 nanobody. Administration of dupilumab and H5 was shown to block IL-4 signaling and subsequently induce FOXJ1 expression. Figure 6c shows that FOXJ1 expression was induced when dupilumab and H5 were treated without IL-4, indicating that the antibody and nanobody did not have any agonistic activity toward the IL-4R. However, FOXJ1 expression was suppressed when treated with both IL-4 and the anti-MBP nanobody, suggesting that the nanobody scaffold itself did not have an antagonistic effect on the IL-4R. Figures 6b and 6c are 3D images of the corresponding HNE samples.
[0258]
[0259] The receptor binding ability of nanobodies was maximized through in-silico affinity maturation.
[0260] For the H5 A110Y and H5 E104R mutations, which were discovered using an artificial intelligence-based structural prediction method and a computer program-based binding affinity enhancement technique, the KD was measured to be 708 nM and 1.06 nM, respectively. Compared to the KD of WT H5 (1.42 μM), a binding affinity increase of up to 2-fold was confirmed (Fig. 8).
[0261]
[0262] We confirmed that the receptor blocking ability of H5 and its substitution mutants and bivalent nanobody was significantly superior to that of dupilumab.
[0263] As a result of analyzing the cell binding affinity and receptor blocking ability of the H5, H5 A110Y mutant and H5 E104R mutant of the present invention and the manufactured bivalent nanobody, it was confirmed that the binding affinity increased by up to 50 times in the case of the bivalent nanobody (Fig. 11). In addition, it was confirmed that the bivalent nanobody was superior to the single nanobody (H5, H5 A110Y mutant and H5 E104R mutant) not only in molecular binding affinity but also in cell binding affinity and receptor blocking ability (Figs. 12a to 12c).
[0264]
[0265] The nanobody of the present invention was confirmed to have superior cell permeability and anti-inflammatory effects compared to dupilumab.
[0266] The results of the air-liquid interface culture experiment showed that H5 was significantly superior to dupilumab in terms of nasal cell permeability (Fig. 16) and inflammation blocking or treatment effect (Figs. 14a, 14b, and 15).
[0267] MUC5AC, CCL26, and FOXJ1 were used as markers for inflammation. MUC5AC is a marker overexpressed by IL-4 / IL-13 signaling, CCL26 is a marker overexpressed by IL-4 / IL-13 signaling, and FOXJ1 is a marker suppressed by IL-4 / IL-13 signaling. In addition, it was confirmed that H5 and H5 bivalent nanobodies had superior paracellular permeability than dupilumab (Fig. 17).
[0268] Meanwhile, the expression of Zo-1 and Occludin, which correspond to tight junction proteins in nasal epithelial cells, was analyzed by measuring the mRNA level, and it was confirmed that the expression was significantly reduced when IL-4 or IL-13 was administered, confirming that cell permeability was increased in patients with inflammatory diseases in which IL-4 or IL-13 was overexpressed (Fig. 18). In summary, considering that the nanobody of the present invention can easily penetrate epithelial cells through its small molecular weight and that tight junctions of nasal cells are reduced in patients with inflammation, it was confirmed that the nanobody of the present invention can be manufactured as a nasal spray formulation and easily pass through the nasal epithelial cells of patients with inflammation, thereby efficiently reducing or eliminating the inflammatory response.
[0269] While specific aspects of the present invention have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
[0270]
[0271] References
[0272] 1. Zimmermann, I. et al. Synthetic single domain antibodies for the conformational trapping of membrane proteins. eLife 7, e34317 (2018).
[0273] 2. Bhattacharjee, N. & Biswas, P. Position-specific propensities of amino acids in the b-strand. 10 (2010).
[0274] 3. Zahnd, C., Amstutz, P. & Pluckthun, A. Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target.Nat. Methods4, 269-279 (2007).
[0275] 4. Zimmermann, I. et al. Generation of synthetic nanobodies against delicate proteins.Nat. Protoc. 15, 1707-1741 (2020).
[0276] 5. Geertsma, E. R. & Dutzler, R. A Versatile and Efficient High-Throughput Cloning Tool for Structural Biology.Biochemistry50, 3272-3278 (2011).
[0277] 6. Mikita, T., Campbell, D., Wu, P., Williamson, K. & Schindler, U. Requirements for interleukin-4-induced gene expression and functional characterization of Stat6.Mol. Cell. Biol.16, 5811-5820 (1996).
[0278] 7. Yu, X. et al. A robust reporter assay for the determination of the bioactivity of IL-4R-targeted therapeutic antibodies.J. Pharm. Biomed. Anal.199, 114033 (2021).
Claims
An anti-IL-4R antibody or antigen-binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 1 comprising a substitution of one or more amino acid residues selected from the group consisting of residues 1.5 and 11.
2. An anti-IL-4R antibody or antigen-binding fragment thereof, characterized in that the substitution of the fifth residue in the first paragraph is a substitution with Arg.
3. An anti-IL-4R antibody or antigen-binding fragment thereof, characterized in that the substitution of the 11th residue in the first paragraph is a substitution with Tyr.
4. An antibody or antigen-binding fragment thereof, characterized in that the anti-IL-4R antibody or antigen-binding fragment thereof in claim 1 comprises at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO:
4. An anti-IL-4R antibody or antigen-binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 5 comprising a substitution of one or more amino acid residues selected from the group consisting of residues 5.104 and 110.
6. An anti-IL-4R antibody or antigen-binding fragment thereof, characterized in that the substitution of the 104th residue in the 5th paragraph is a substitution with Arg.
7. An anti-IL-4R antibody or antigen-binding fragment thereof, characterized in that the substitution of the 110th residue in the 5th paragraph is a substitution with Tyr.
8. In paragraph 5, the anti-IL-4R antibody or antigen-binding fragment thereof is characterized in that it comprises at least one amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO:
8.
9. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, characterized in that the antigen-binding fragment is a nanobody.
10. An antibody or antigen-binding fragment thereof, characterized in that the nanobody in claim 9 has a convex scaffold structure.
11. Two identical or different antibodies or antigen-binding fragments selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7 and 8; and an antibody or antigen-binding fragment in the form of a dimer comprising a linker.
12. In claim 11, the dimeric antibody or antigen-binding fragment is characterized in that it is composed of two antigens composed of SEQ ID NO: 5 and a linker connecting them.
13. In claim 11, the dimeric antibody or antigen-binding fragment is characterized in that it is composed of two antigens composed of SEQ ID NO: 6 and a linker connecting them.
14. An antibody or antigen-binding fragment in dimer form, characterized in that the antibody in dimer form is composed of two antigens composed of sequence number 7 and a linker connecting them.
15. An antibody or antigen-binding fragment in dimer form, characterized in that the antibody in dimer form comprises two antigens composed of SEQ ID NO: 8 and a linker connecting them.
16. An antibody or antigen-binding fragment in the form of a dimer according to any one of claims 11 to 15, wherein the linker is composed of three amino acids.
17. An antibody or antigen-binding fragment in a dimer form, characterized in that the linker is a peptide consisting of SEQ ID NO: 9 in the 16th paragraph.
18. A nucleic acid molecule encoding an antibody or antigen-binding fragment thereof according to any one of claims 1, 5 and 11.
19. A pharmaceutical composition for preventing or treating an inflammatory disease or an autoimmune disease, comprising as an active ingredient an antibody or an antigen-binding fragment thereof according to any one of claims 1, 5, and 11; or a nucleic acid molecule according to claim 18.
20. In claim 19, the inflammatory or autoimmune disease is rhinitis, conjunctivitis, periodontitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, rheumatoid arthritis, polymyalgia rheumatica, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, periarthritis of the shoulder joint, tendinitis, tenosynovitis, peritendinitis, myositis, polymyositis, dermatomyositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, multiple sclerosis, inflammatory bowel disease, asthma, type 1 diabetes, psoriasis, eczema, scleroderma, vitiligo, peripheral neuritis, uveitis, autoimmune cytopenia, autoimmune myocarditis, atopic dermatitis, primary liver cirrhosis, A composition characterized by inflammation selected from the group consisting of dry eye syndrome, Goodfeiter syndrome, autoimmune meningitis, Addison's disease, autoimmune parotitis, dystrophic epidermolysis bullosa, epididymitis, glomerulonephritis, Graves' disease, celiac disease, Guillain-Barré syndrome, Hashimoto's disease, hemolytic anemia, myasthenia gravis, amyotrophic lateral sclerosis, pemphigus vulgaris, sarcoidosis, spondyloarthropathy, thyroiditis, vasculitis, myxedema, pernicious anemia, antiphospholipid syndrome, and graft-versus-host disease.
21. A composition according to claim 20, wherein the rhinitis is nasal polyps or sinusitis.
22. A composition according to claim 21, characterized in that the sinusitis is chronic sinusitis (CRS).
23. A composition according to claim 22, wherein the chronic sinusitis is chronic sinusitis with nasal polyps (CRS with nasal polyp, CRSwNP).
24. A composition according to claim 19, characterized in that the composition is a composition for nasal administration.
Citation Information
Patent Citations
Process for the purification of recombinant polypeptides
WO1988007085A1
Leader sequences for the production of recombinant proteins
WO1988007086A1
Targeted multifunctional proteins
WO1988009344A1
Anti-IL-4R alpha single-domain antibody, application and drug
CN111690066A
High affinity human antibodies to human IL-4 receptor
KR1020110074980A
